Move Over Roivant, Nuvation: EQRx Reveals Biggest Biopharma SPAC Merger This Year
Deal Gives Developer Of Low-Cost Drugs $1.8bn In New Cash
EQRx has raised at least $750m since it launched in January 2020 and will have $2bn to fund its ongoing development of low-cost drugs after merging with a special purpose acquisition corporation.
